Jennifer E Schuster1, Najwa Khuri-Bulos, Samir Faouri, Asem Shehabi, Monika Johnson, Li Wang, Christopher Fonnesbeck, John V Williams, Natasha Halasa. 1. From the *Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri; †Department of Pediatrics, Jordan University, Amman, Jordan; ‡Department of Pediatrics, Al Bashir Hospital, Amman, Jordan; §Department of Pediatrics, ¶Department of Biostatistics, Vanderbilt University, Nashville, Tennessee; and ‖Department of Pediatrics, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Human metapneumovirus (HMPV) is a leading cause of acute respiratory tract infection in young children. Our objectives were to define HMPV epidemiology and circulating strains and determine markers of severe disease in Jordanian children. METHODS: We conducted a prospective study from March 16, 2010 to March 31, 2013 using quantitative reverse transcription-polymerase chain reaction to determine the frequency of HMPV infection among children <2 years old admitted with fever and/or acute respiratory illness to a major government hospital in Amman, Jordan. RESULTS: HMPV was present in 273 of 3168 (8.6%) of children presenting with acute respiratory tract infection. HMPV A2, B1 and B2, but not A1, were detected during the 3-year period. HMPV-infected children were older and more likely to be diagnosed with bronchopneumonia than HMPV-negative children. HMPV-infected children with lower respiratory tract infection had higher rates of cough and shortness of breath than children with lower respiratory tract infection infected with other or no identifiable viruses. Symptoms and severity were not different between children with HMPV only compared with HMPV coinfection. Children with HMPV subgroup A infection were more likely to require supplemental oxygen. In a multivariate analysis, HMPV subgroup A and age <6 months were independently associated with supplemental oxygen requirement. CONCLUSIONS: HMPV is a leading cause of acute respiratory tract disease in Jordanian children <2 years old. HMPV A and young age were associated with severe disease. Ninety percent of HMPV-infected hospitalized children were full term and otherwise healthy, in contrast to high-income nations; thus, factors contributing to disease severity likely vary depending on geographic and resource differences.
BACKGROUND:Human metapneumovirus (HMPV) is a leading cause of acute respiratory tract infection in young children. Our objectives were to define HMPV epidemiology and circulating strains and determine markers of severe disease in Jordanian children. METHODS: We conducted a prospective study from March 16, 2010 to March 31, 2013 using quantitative reverse transcription-polymerase chain reaction to determine the frequency of HMPV infection among children <2 years old admitted with fever and/or acute respiratory illness to a major government hospital in Amman, Jordan. RESULTS:HMPV was present in 273 of 3168 (8.6%) of children presenting with acute respiratory tract infection. HMPV A2, B1 and B2, but not A1, were detected during the 3-year period. HMPV-infected children were older and more likely to be diagnosed with bronchopneumonia than HMPV-negative children. HMPV-infected children with lower respiratory tract infection had higher rates of cough and shortness of breath than children with lower respiratory tract infection infected with other or no identifiable viruses. Symptoms and severity were not different between children with HMPV only compared with HMPV coinfection. Children with HMPVsubgroupA infection were more likely to require supplemental oxygen. In a multivariate analysis, HMPVsubgroup A and age <6 months were independently associated with supplemental oxygen requirement. CONCLUSIONS:HMPV is a leading cause of acute respiratory tract disease in Jordanian children <2 years old. HMPV A and young age were associated with severe disease. Ninety percent of HMPV-infected hospitalized children were full term and otherwise healthy, in contrast to high-income nations; thus, factors contributing to disease severity likely vary depending on geographic and resource differences.
Authors: John V Williams; Chiaoyin K Wang; Chin-Fen Yang; Sharon J Tollefson; Frances S House; Josh M Heck; Marla Chu; Jennifer B Brown; Linda D Lintao; Joe D Quinto; David Chu; Richard R Spaete; Kathryn M Edwards; Peter F Wright; James E Crowe Journal: J Infect Dis Date: 2005-12-30 Impact factor: 5.226
Authors: Jennifer Klemenc; S Asad Ali; Monika Johnson; Sharon J Tollefson; H Keipp Talbot; Tina V Hartert; Kathryn M Edwards; John V Williams Journal: J Clin Virol Date: 2012-06-06 Impact factor: 3.168
Authors: Kathryn M Edwards; Yuwei Zhu; Marie R Griffin; Geoffrey A Weinberg; Caroline B Hall; Peter G Szilagyi; Mary A Staat; Marika Iwane; Mila M Prill; John V Williams Journal: N Engl J Med Date: 2013-02-14 Impact factor: 91.245
Authors: Eun Hwa Choi; Hoan Jong Lee; Sun Jung Kim; Byung Wook Eun; Nam Hee Kim; Jin A Lee; Jun Ho Lee; Eun Kyung Song; So Hee Kim; Ji Yong Park; Ji Yeon Sung Journal: Clin Infect Dis Date: 2006-07-26 Impact factor: 9.079
Authors: Julie Greensill; Paul S McNamara; Winifred Dove; Brian Flanagan; Rosalind L Smyth; C Anthony Hart Journal: Emerg Infect Dis Date: 2003-03 Impact factor: 6.883
Authors: María Luz García-García; Cristina Calvo; Cristina Rey; Beatriz Díaz; Maria Del Mar Molinero; Francisco Pozo; Inmaculada Casas Journal: PLoS One Date: 2017-03-16 Impact factor: 3.240
Authors: Nina Moe; Sidsel Krokstad; Inger Heimdal Stenseng; Andreas Christensen; Lars Høsøien Skanke; Kari Ravndal Risnes; Svein Arne Nordbø; Henrik Døllner Journal: PLoS One Date: 2017-01-17 Impact factor: 3.240
Authors: Najwa Khuri-Bulos; Lindsey Lawrence; Bhinnata Piya; Li Wang; Christopher Fonnesbeck; Samir Faouri; Asem Shehabi; Sten H Vermund; John V Williams; Natasha B Halasa Journal: BMJ Open Date: 2018-05-20 Impact factor: 2.692